STAT+: The quest to save Grace — and clear the way for rare disease patients everywhere

STAT NewsIndependentCenteryesterday

The article discusses a father's efforts to develop gene therapy for his daughter suffering from NGLY1 deficiency, a rare genetic disorder. Matt Wilsey founded a company with significant funding and recruited experts to create an experimental treatment. The treatment initially caused Grace to relapse but eventually led to her recovery. The article also mentions other developments in biotechnology, including the White House considering a new FDA chief and the Trump administration encouraging pharmaceutical companies to bring generic drug production back to the U.S.

Bias read (Center): The article covers biotechnology advancements and mentions political actions by the Trump administration regarding drug manufacturing, but it does not exhibit clear ideological bias in its framing or sourcing.

STAT NewsIndependentCenteryesterday

The article discusses two separate topics. First, it highlights Matt Wilsey's efforts to develop a gene therapy for his daughter's rare genetic condition, NGLY1 deficiency, and the potential challenges he faces in getting FDA approval due to regulatory requirements and financial constraints. Second, it mentions the ongoing search for a new FDA commissioner, with finalists being considered by the White House, highlighting the agency's current instability following recent leadership changes and internal turmoil. The piece also briefly references a study published in eClinicalMedicine suggesting a higher risk of neurodegenerative diseases among professional football players.

Bias read (Center): The article presents information about the FDA's regulatory processes and leadership transition without overtly favoring any particular political ideology. It provides balanced reporting on both the medical case and the political implications of FDA leadership changes, though it does include some nu

STAT NewsIndependentCenteryesterday

Matt Wilsey, a father whose daughter Grace suffers from NGLY1 deficiency—a rare and fatal genetic disorder—has invested over $70 million into developing a gene therapy aimed at treating her condition. Despite successfully treating 10 patients, including Grace, in a clinical trial, Wilsey's company lacks the necessary funding and regulatory approval from the FDA. Wilsey continues to push for approval, positioning his efforts as a critical precedent for the treatment of rare diseases. Grace received the experimental gene therapy, which was intended to extend her life and potentially enable her to speak, though it led to a deterioration in her health, requiring hospitalization. Wilsey's journey highlights both the personal stakes involved and the broader implications for medical research targeting rare conditions.

Bias read (Center): The article focuses on a rare disease and the development of a potential treatment, which is primarily a medical and scientific issue. While the involvement of the FDA and the implications for pharmaceutical regulation introduce some political elements, the overall framing remains centered on the bi